Citations

Clear

3942 citation(s) found for "To, Van".

Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort
Rhun, Émilie Le , Devos, Patrick , Winklhofer, Sebastian , Lmalem, Hafida, Brandsma, Dieta , Kumthekar, Priya , Castellano, Antonella , Compter, Annette , Dhermain, F., Franceschi, Enrico , Gempt, Jens , Hattingen, Elke , Hempel, Johann, Lukacova, Slávka , Minniti, Giuseppe , O’Brien, Barbara , Postma, Tjeerd J., Roth, Patrick , Schaefer, Niklaus , Thust, Steffi, Bent, Martin J. van den , Hoorn, Anouk van der , Vogin, Guillaume , Smits, Marion , Jaeckle, Kurt A. , Preusser, Matthias , Glantz, Michael , Wen, Patrick Y. , Weller, Michael , Le Rhun, Emilie , Gállego Pérez-Larraya, Jaime , Snijders, Tom J , Smits, Marion , Jaeckle, Kurt A , Preusser, Matthias , Weller, Michael , van den Bent, Martin J , Franceschi, Enrico , Roth, Patrick , Forsyth, Peter A , Furtner, Julia , Galldiks, Norbert , Rudà, Roberta , Schmidt, Nils Ole , Thust, Stefanie Catherine , Tonn, Joerg-Christian , Wen, Patrick Yung , Bendszus, Martin

Mayo Clinic

Neuro-Oncology | February 11, 2022 | Volume: 24 | Issue: 10 | Pages: 1726-1735

10.1093/neuonc/noac043 | PMID 35157772 Get It

Abstract Background Validation of the 2016 RANO MRI scorecard for leptomeningeal metastasis failed for multiple reasons. Accordingly, this joint EORTC Brain Tumor Group and RANO effort sought to prospectively validate a revised MRI scorecard for response assessment in leptomeningeal metastasis. Methods Coded paired cerebrospinal MRI of 20 patients with leptomeningeal metastases from solid cancers at baseline and follow-up after treatment and instructions for assessment were provided via the EORTC imaging platform. The Kappa coefficient was used to evaluate the interobserver pairwise agreement. Results Thirty-five raters participated, including 9 neuroradiologists, 17 neurologists, 4 radiation oncologists, 3 neurosurgeons, and 2 medical oncologists. Among single leptomeningeal metastases-related imaging findings at baseline, the best median concordance was noted for hydrocephalus (Kappa = 0.63), and the worst median concordance for spinal linear enhancing disease (Kappa = 0.46). The median concordance of raters for the overall response assessment was moderate (Kappa = 0.44). Notably, the interobserver agreement for the presence of parenchymal brain metastases at baseline was fair (Kappa = 0.29) and virtually absent for their response to treatment. 394 of 700 ratings (20 patients x 35 raters, 56%) were fully completed. In 308 of 394 fully completed ratings (78%), the overall response assessment perfectly matched the summary interpretation of the single ratings as proposed in the scorecard instructions. Conclusion This study confirms the principle utility of the new scorecard, but also indicates the need for training of MRI assessment with a dedicated reviewer panel in clinical trials. Electronic case report forms with “blocking options” may be required to enforce completeness and quality of scoring.
Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging
Krell‐Roesch, Janina , Rakuša, Martin , Syrjanen, Jeremy A. , Harten, Argonde C. van , Lowe, Val J. , Jack, Clifford R. , Kremers, Walter K. , Petersen, Ronald C. , Vassilaki, Maria , Geda, Yonas E. , Geda, Yonas E , Jack, Clifford R , Kremers, Walter K , Knopman, David S. , Stokin, Gorazd B.

Mayo Clinic

Alzheimer's & Dementia | February 10, 2022 | Volume: 19 | Issue: 10 | Pages: 4498-4506

10.1002/alz.12557 | PMID 35142047 Get It

Abstract Introduction We examined the association between cerebrospinal fluid (CSF)‐derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms (NPS) in older non‐demented adults. Methods We included 784 persons (699 cognitively unimpaired, 85 with mild cognitive impairment) aged ≥ 50 years who underwent CSF amyloid beta (Aβ42), hyperphosphorylated tau 181 (p‐tau), and total tau (t‐tau) as well as NPS assessment using Beck Depression and Anxiety Inventories (BDI‐II, BAI), and Neuropsychiatric Inventory Questionnaire (NPI‐Q). Results Lower CSF Aβ42, and higher t‐tau/Aβ42 and p‐tau/Aβ42 ratios were associated with BDI‐II and BAI total scores, clinical depression (BDI‐II ≥ 13), and clinical anxiety (BAI ≥ 10), as well as NPI‐Q–assessed anxiety, apathy, and nighttime behavior. Discussion CSF Aβ42, t‐tau/Aβ42, and p‐tau/Aβ42 ratios were associated with NPS in community‐dwelling individuals free of dementia. If confirmed by a longitudinal cohort study, the findings have clinical relevance of taking into account the NPS status of individuals with abnormal CSF biomarkers.
The MIDA quantitative international registry: prognostic implications of moderately elevated pulmonary artery pressure
Antoine, C., Roussel, J.C., Ajmone, N, Wijngaarden, Aniek Van, Tribouilloy, C, Topilsky, Y, Essayagh, Benjamin , Benfari, Giovanni , Grigioni, Francesco , Tourneau, Thierry Le , Delgado, Victoria , Bax, Jeroen J. , Hochstadt, Aviram , Topilsky, Y, Michelena, Héctor I. , Enriquez‐Sarano, Maurice

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | February 9, 2022 | Volume: 23 | Issue: Supplement_1 | Pages: No page available

10.1093/ehjci/jeab289.204 Get It

Abstract Funding Acknowledgements Type of funding sources: None. Background Pulmonary hypertension is a frequent complication of severe degenerative mitral regurgitation (DMR) associated with major outcome implications. However, whether pulmonary hypertension is linked with worse outcome in less that severe MR is uncertain and even more unsubstantiated is the link of elevated systolic pulmonary artery pressure (sPAP) < 50mmHg with clinical presentation and outcome. Purpose To assess the outcome implication of sPAP elevation, even moderate, among mitral regurgitation severity subgroups. Methods The MIDA-Quantitative (MIDA-Q) unprecedented registries included 7373 consecutive patients (age 64 ± 17 years, 45% women, follow-up 5.5 ± 3.4 years) with isolated DMR diagnosed at tertiary (European/North-American/Middle East) centers in which systolic pulmonary artery pressure (sPAP) was measured prospectively at baseline. Long-term survival overall, under medical management and post-mitral surgery was analyzed. Results Elevated pulmonary pressure (sPAP >50mmHg) was observed in 1371 patients (19%, mean 63 ± 13mmHg) and moderate increase in pulmonary pressure (35< sPAP < 50mmHg) in 1874 patients (25%, mean 41 ± 14mmHg), with no/mild MR in 4067 (50%), moderate in 2073 (25%), and severe or above in 2047 (25%), mean ERO 0.24 ± 24cm2, RVol 37 ± 35mL and posterior leaflet prolapse in 34%. sPAP severe but also moderate both strongly and independently linked to more severe clinical presentation, with more dyspnea, more AFib, and impaired renal function (P ≤ 0.0001). <SPAP< >By sPAP categories, 35 < sPAP< 50mmHg (vs. 35mmHg) was independently associated with worse outcome under medical management adjusted-HR 1.62[1.40-1/87], with considerable excess-mortality for sPAP > 50mmHg (vs. <35mmHg) adjusted-HR 2.54[2.17-2.96], all P < 0.0001. As continuous variable, sPAP was associated with worse outcome adjusted-HR 1.25[1.21-1.29], P < 0.0001 per 10mmHg-increase. Mitral valve surgery (performed in 2378 patients, 32%) improved outcome without alleviating completely higher mortality associated with sPAP > 50mmHg (P < 0.0001). Conclusion In this very large international cohort of patients with DMR of all range and prospective sPAP grading, higher sPAP is associated at diagnosis with more severe clinical presentation. Long term, sPAP > 50mmHg but also 35-50mmHg is independently of all confounders, associated with worse mortality. Thus careful assessment and consideration for mitral surgery/transcatheter therapy is warranted even in patients with sPAP <50mmHg.</SPAP< > Abstract Figure. Survival stratified by sPAP Categories Abstract Figure. Postop survival by sPAP Categories
Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
Pelkmans, Wiesje , Vromen, Eleonora M. , Dicks, Ellen , Teunissen, Charlotte E. , Barkhof, Frederik , Tijms, Betty M. , Initiative, for the Alzheimer’s Disease Neuroimaging, Teunissen, Charlotte E , Tijms, Betty M , Barkhof, Frederik , Scheltens, Philip , Flier, Wiesje M. van der , Initiative, for the Alzheimer’s Disease Neuroimaging

Mayo Clinic

Brain Communications | February 7, 2022 | Volume: 4 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcac026 | PMID 35310828 Get It

AbstractIndividuals with prodromal Alzheimer’s disease show considerable variability in rates of cognitive decline, which hampers the ability to detect potential treatment effects in clinical trials. Prognostic markers to select those individuals who will decline rapidly within a trial time frame are needed. Brain network measures based on grey matter covariance patterns have been associated with future cognitive decline in Alzheimer’s disease. In this longitudinal cohort study, we investigated whether cut-offs for grey matter networks could be derived to detect fast disease progression at an individual level. We further tested whether detection was improved by adding other biomarkers known to be associated with future cognitive decline [i.e. CSF tau phosphorylated at threonine 181 (p-tau181) levels and hippocampal volume]. We selected individuals with mild cognitive impairment and abnormal CSF amyloid β1–42 levels from the Amsterdam Dementia Cohort and the Alzheimer’s Disease Neuroimaging Initiative, when they had available baseline structural MRI and clinical follow-up. The outcome was progression to dementia within 2 years. We determined prognostic cut-offs for grey matter network properties (gamma, lambda and small-world coefficient) using time-dependent receiver operating characteristic analysis in the Amsterdam Dementia Cohort. We tested the generalization of cut-offs in the Alzheimer’s Disease Neuroimaging Initiative, using logistic regression analysis and classification statistics. We further tested whether combining these with CSF p-tau181 and hippocampal volume improved the detection of fast decliners. We observed that within 2 years, 24.6% (Amsterdam Dementia Cohort, n = 244) and 34.0% (Alzheimer’s Disease Neuroimaging Initiative, n = 247) of prodromal Alzheimer’s disease patients progressed to dementia. Using the grey matter network cut-offs for progression, we could detect fast progressors with 65% accuracy in the Alzheimer’s Disease Neuroimaging Initiative. Combining grey matter network measures with CSF p-tau and hippocampal volume resulted in the best model fit for classification of rapid decliners, increasing detecting accuracy to 72%. These data suggest that single-subject grey matter connectivity networks indicative of a more random network organization can contribute to identifying prodromal Alzheimer’s disease individuals who will show rapid disease progression. Moreover, we found that combined with p-tau and hippocampal volume this resulted in the highest accuracy. This could facilitate clinical trials by increasing chances to detect effects on clinical outcome measures.
Concomitant Sepsis Diagnoses in Acute Myocardial Infarction-Cardiogenic Shock: 15-Year National Temporal Trends, Management, and Outcomes
Bhat, Anusha Ganapati , Patlolla, Sri Harsha , Miller, P. Elliott , Lawler, Patrick R. , Zhao, David , Vallabhajosyula, Saraschandra , Vallabhajosyula, Saraschandra , Lawler, Patrick , Harsha Patlolla, Sri , Jentzer, Jacob C. , Sinha, Shashank S , Diepen, Sean van , Khanna, Ashish K.

Mayo Clinic

Critical Care Explorations | February 4, 2022 | Volume: 4 | Issue: 2 | Pages: e0637

10.1097/cce.0000000000000637 | PMID 35141527 Get It

OBJECTIVES: Mixed cardiogenic-septic shock is common and associated with high mortality. There are limited contemporary data on concomitant sepsis in acute myocardial infarction complicated by cardiogenic shock (AMI-CS). DESIGN: Observational study. SETTING: Twenty percent stratified sample of all community hospitals (2000–2014) in the United States. PARTICIPANTS: Adults (> 18 yr) with AMI-CS with and without concomitant sepsis. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Outcomes of interest included inhospital mortality, development of noncardiac organ failure, complications, utilization of guideline-directed procedures, length of stay, and hospitalization costs. Over 15 years, 444,253 AMI-CS admissions were identified, of which 27,057 (6%) included sepsis. The sepsis cohort had more comorbidities and had higher rates of noncardiac multiple organ failure (92% vs 69%) (all p < 0.001). In 2014, compared with 2000, the prevalence of sepsis increased from 0.5% versus 11.5% with an adjusted odds ratio (aOR) 11.71 (95% CI, 9.7–14.0) in ST-segment elevation myocardial infarction and 24.6 (CI, 16.4–36.7) (all p < 0.001) in non-ST segment elevation myocardial infarction. The sepsis cohort received fewer cardiac interventions (coronary angiography [65% vs 68%], percutaneous coronary intervention [43% vs 48%]) and had greater use of mechanical circulatory support (48% vs 45%) and noncardiac support (invasive mechanical ventilation [65% vs 41%] and acute hemodialysis [12% vs 3%]) (p < 0.001). The sepsis cohort had higher inhospital mortality (44.3% vs 38.1%; aOR, 1.21; 95% CI, 1.18–1.25; p < 0.001), longer length of stay (14.0 d [7–24 d] vs 7.0 d [3–12 d]), greater hospitalization costs (×1,000 U.S. dollars) ($176.0 [$85–$331] vs $77.0 [$36–$147]), fewer discharges to home (22% vs 44%) and more discharges to skilled nursing facilities (51% vs 28%) (all p < 0.001). CONCLUSIONS: In AMI-CS, concomitant sepsis is associated with higher mortality and morbidity highlighting the need for early recognition and integrated management of mixed shock.
Predictive Value of Ki-67 Index in Evaluating Sporadic Vestibular Schwannoma Recurrence: Systematic Review and Meta-analysis
Vakharia, Kunal , Graffeo, Christopher S. , Cohen-Cohen, Salomón , Perry, Avital , Carlson, Matthew L. , Driscoll, Colin L. W., Peris‐Celda, Maria , Gompel, Jamie J. Van , Link, Michael J. , Graffeo, Christopher, Cohen-Cohen, Salomon , Van Gompel, Jamie J , Hasegawa, Hirotaka , Noureldine, Mohammad Hassan A.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 4, 2022 | Volume: 84 | Issue: 02 | Pages: 119-128

10.1055/a-1760-2126 | PMID 36895813 Get It

Abstract Introduction Ki-67 is often used as a proliferation index to evaluate how aggressive a tumor is and its likelihood of recurrence. Vestibular schwannomas (VS) are a unique benign pathology that lends itself well to evaluation with Ki-67 as a potential marker for disease recurrence or progression following surgical resection. Methods All English language studies of VSs and Ki-67 indices were screened. Studies were considered eligible for inclusion if they reported series of VSs undergoing primary resection without prior irradiation, with outcomes including both recurrence/progression and Ki-67 for individual patients. For published studies reporting pooled Ki-67 index data without detailed by-patient values, we contacted the authors to request data sharing for the current meta-analysis. Studies reporting a relationship between Ki-67 index and clinical outcomes in VS for which detailed patients' outcomes or Ki-67 indices could not be obtained were incorporated into the descriptive analysis, but excluded from the formal (i.e., quantitative) meta-analysis. Results A systematic review identified 104 candidate citations of which 12 met inclusion criteria. Six of these studies had accessible patient-specific data. Individual patient data were collected from these studies for calculation of discrete study effect sizes, pooling via random-effects modeling with restricted maximum likelihood, and meta-analysis. The standardized mean difference in Ki-67 indices between those with and without recurrence was calculated as 0.79% (95% confidence interval [CI]: 0.28–1.30; p = 0.0026). Conclusion Ki-67 index may be higher in VSs that demonstrate recurrence/progression following surgical resection. This may represent a promising means of evaluating tumor recurrence and potential need for early adjuvant therapy for VSs.
Therapeutic endoscopic ultrasound: European Society of Gastrointestinal Endoscopy (ESGE) Technical Review
Wanrooij, Roy L.J. van , Bronswijk, Michiel , Kunda, Rastislav , Rimbaș, Mihai , Hucl, Tomáš , Badaoui, Abdenor , Law, Ryan , Arcidiacono, Paolo Giorgio , Giovannini, Marc , Khashab, Mouen A., Binmoeller, Kenneth F., Hooft, Jeanin E. van , Merwe, Van der , van Wanrooij, Roy L J , Rimbas, Mihai , Barthet, Marc , Perez-Miranda, Manuel , van Hooft, Jeanin E , Arcidiacono, Paolo Giorgio , Everett, Simon M , Lakhtakia, Sundeep , Larghi, Alberto , Khashab, Mouen A. , Pérez‐Miranda, Manuel

Mayo Clinic

Endoscopy | February 3, 2022 | Volume: 54 | Issue: 03 | Pages: 310-332

10.1055/a-1738-6780 | PMID 35114696 Get It

Main Recommendations 1 ESGE recommends a prolonged course of a prophylactic broad-spectrum antibiotic in patients with ascites who are undergoing therapeutic endoscopic ultrasound (EUS) procedures.Strong recommendation, low quality evidence. 2 ESGE recommends placement of partially or fully covered self-expandable metal stents during EUS-guided hepaticogastrostomy for biliary drainage in malignant disease.Strong recommendation, moderate quality evidence. 3 ESGE recommends EUS-guided pancreatic duct (PD) drainage should only be performed in high volume expert centers, owing to the complexity of this technique and the high risk of adverse events.Strong recommendation, low quality evidence. 4 ESGE recommends a stepwise approach to EUS-guided PD drainage in patients with favorable anatomy, starting with rendezvous-assisted endoscopic retrograde pancreatography (RV-ERP), followed by antegrade or transmural drainage only when RV-ERP fails or is not feasible.Strong recommendation, low quality evidence. 5 ESGE suggests performing transduodenal EUS-guided gallbladder drainage with a lumen-apposing metal stent (LAMS), rather than using the transgastric route, as this may reduce the risk of stent dysfunction.Weak recommendation, low quality evidence. 6 ESGE recommends using saline instillation for small-bowel distension during EUS-guided gastroenterostomy.Strong recommendation, low quality evidence. 7 ESGE recommends the use of saline instillation with a 19G needle and an electrocautery-enhanced LAMS for EUS-directed transgastric endoscopic retrograde cholangiopancreatography (EDGE) procedures.Strong recommendation, low quality evidence. 8 ESGE recommends the use of either 15- or 20-mm LAMSs for EDGE, with a preference for 20-mm LAMSs when considering a same-session ERCP.Strong recommendation, low quality evidence.
Dementia with Lewy bodies subtypes identified by cluster analysis on structural MRI
Przybelski, Scott A. , Beek, Marleen van de , Sousa, Paulo Loureiro de , Philippi, Nathalie , Demuynck, Catherine, Oppedal, Ketil , Inguanzo, Anna , Poulakis, Konstantinos , Mohanty, Rosaleena , Schwarz, Christopher G. , Lemstra, Afina W. , Flier, Wiesje M. van der , Barkhof, Frederik , Blanc, Frédéric , Cretin, Benjamin , Nedelská, Zuzana , Hort, Jakub , Segura, Bàrbara , Junqué, Carme , Aarsland, Dag , Westman, Eric , Kantarci, Kejal , Ferreira, Daniel

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S4 | Pages: No page available

10.1002/alz.053573 Get It

AbstractBackgroundDementia with Lewy bodies (DLB) is a neurodegenerative disorder that presents with a variety of clinical symptoms. Part of the clinical heterogeneity within DLB has been related to the atrophy/sparing of the hippocampus. We extended that previous research by investigating whether different atrophy patterns exist in DLB, beyond and above the atrophy/sparing of the hippocampus, and whether those patterns contribute to the clinical heterogeneity in DLB. We aimed to identify DLB atrophy subtypes using a hypothesis‐free data‐driven clustering approach based on regional gray matter (GM) volumes and characterize the resulting subtypes across key measures.MethodWe included data from three centers of the European DLB consortium. A high‐resolution 3D T1‐weigthed magnetization prepared rapid gradient echo (MPRAGE) sequence was acquired for 97 DLB patients. Eighty‐four cortical regions and 12 subcortical regions from Mayo Clinic Adult Lifespan Template (https://www.nitrc.org/projects/mcalt/) atlases were obtained. Clusters of DLB patients were then determined using the random forest method. Between‐group differences in key demographic, clinical, MRI volumes and cerebrospinal fluid biomarkers (CSF) (amyloid‐beta, phosphorylated‐tau) were performed for clusters characterization.ResultWe identified three subtypes of DLB patients, with distinct patterns of GM volumes and differences in several clinical and demographic measures. Cluster 1 (C1) included 32 DLB patients (33%), cluster 2 (C2) included 29 DLB patients (30%), and cluster 3 (C3) included 36 DLB patients (37%). The clusters differed in age, with C1 being significantly older (72±8.6) than C3 (66±9.5) (F=3.93, p=0.02). C1 was characterized by lower volumes in fronto‐temporal regions and had a higher frequency of visual hallucinations (68%, vs. C2 35%). C2 showed lower volumes in occipital regions. C3 had higher GM volumes overall compared with the other two clusters and presented with a higher frequency of cognitive fluctuations (91%, vs. C1 67%). There were no differences between groups in CSF biomarkers. These results were independent of cluster differences in age and global GM volume.ConclusionThere are distinct patterns of brain atrophy in patients with DLB. These patterns seem to differentially contribute to the frequencies of visual hallucinations and cognitive fluctuations, independently of differences in age and global GM volume across subtypes.
Atrial fibrillation in partial anomalous pulmonary venous return: right atrial drainage from one vein and epicardial conduction from another vein
Bhalla, Jaideep Singh , Zyl, Martin van , Madhavan, Malini , Bhalla, Jaideep

Mayo Clinic

EP Europace | February 1, 2022 | Volume: 24 | Issue: 9 | Pages: 1459-1459

10.1093/europace/euac006 | PMID 35357427 Get It

Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration
Rivard, Léna , Friberg, Leif , Conen, David , Healey, Jeff S. , Berge, Trygve , Boriani, Giuseppe , Brandes, Axel , Calkins, Hugh , Camm, A. John , Espuny, Josep Lluis Clua , Collins, Ronan, Connolly, Stuart, Dagres, Nikolaos , Elkind, Mitchell S.V. , Engdahl, Johan, Field, Thalia S. , Glotzer, Taya V., Hankey, Graeme J. , Hills, Mellanie True , Johnson, Linda S.B. , Joung, Boyoung, Krieger, Derk, Løchen, Maja-Lisa, Madhavan, Malini, Mairesse, Georges H., Montaner, Joan , Rienstra, Michiel , Rosenqvist, Mårten, Sandhu, Roopinder K., Smyth, Breda, Stavrakis, Stavros , Gelder, Isabelle C. Van, Wang, Ji‐Guang , Freedman, Ben , Joung, Boyoung , Healey, Jeffrey S , Chen, Lin Y , Lluis Clua Espuny, Josep , Dagres, Nikolaos , Elkind, Mitchell S V , Field, Thalia S , Gersh, Bernard J , Hankey, Graeme J , Harbison, Joseph A , Haeusler, Karl G , True Hills, Mellanie , Johnson, Linda S B , Khairy, Paul , Kirchhof, Paulus , Lip, Gregory Y H , Montaner, Joan , Ntaios, George , Quinn, Terence J , Rienstra, Michiel , Schnabel, Renate B , Stavrakis, Stavros , Themistoclakis, Sakis , Wang, Ji-Guang , Freedman, Ben , Boriani, Giuseppe , Joung, Boyoung , Brandes, Axel , Rivard, Lena , Friberg, Leif , Conen, David , Berge, Trygve , Calkins, Hugh , Camm, Alan John , Collins, Ronan, Connolly, Stuart, Engdahl, Johan, Glotzer, Taya V., Krieger, Derk, Løchen, Maja-Lisa, Madhavan, Malini, Mairesse, Georges H., Rosenqvist, Mårten, Sandhu, Roopinder K., Smyth, Breda, Gelder, Isabelle C. Van

Mayo Clinic

Circulation | January 31, 2022 | Volume: 145 | Issue: 5 | Pages: 392-409

10.1161/circulationaha.121.055018 | PMID 35100023 Get It

Growing evidence suggests a consistent association between atrial fibrillation (AF) and cognitive impairment and dementia that is independent of clinical stroke. This report from the AF-SCREEN International Collaboration summarizes the evidence linking AF to cognitive impairment and dementia. It provides guidance on the investigation and management of dementia in patients with AF on the basis of best available evidence. The document also addresses suspected pathophysiologic mechanisms and identifies knowledge gaps for future research. Whereas AF and dementia share numerous risk factors, the association appears to be independent of these variables. Nevertheless, the evidence remains inconclusive regarding a direct causal effect. Several pathophysiologic mechanisms have been proposed, some of which are potentially amenable to early intervention, including cerebral microinfarction, AF-related cerebral hypoperfusion, inflammation, microhemorrhage, brain atrophy, and systemic atherosclerotic vascular disease. The mitigating role of oral anticoagulation in specific subgroups (eg, low stroke risk, short duration or silent AF, after successful AF ablation, or atrial cardiopathy) and the effect of rhythm versus rate control strategies remain unknown. Likewise, screening for AF (in cognitively normal or cognitively impaired patients) and screening for cognitive impairment in patients with AF are debated. The pathophysiology of dementia and therapeutic strategies to reduce cognitive impairment warrant further investigation in individuals with AF. Cognition should be evaluated in future AF studies and integrated with patient-specific outcome priorities and patient preferences. Further large-scale prospective studies and randomized trials are needed to establish whether AF is a risk factor for cognitive impairment, to investigate strategies to prevent dementia, and to determine whether screening for unknown AF followed by targeted therapy might prevent or reduce cognitive impairment and dementia.